2. Academic Validation
  3. Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor

Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor

  • Bioorg Med Chem Lett. 2008 May 1;18(9):2985-9. doi: 10.1016/j.bmcl.2008.03.057.
Réjean Ruel 1,  Carl Thibeault,  Alexandre L'Heureux,  Alain Martel,  Zhen-Wei Cai,  Donna Wei,  Ligang Qian,  Joel C Barrish,  Arvind Mathur,  Celia D'Arienzo,  John T Hunt,  Amrita Kamath,  Punit Marathe,  Yueping Zhang,  George Derbin,  Barri Wautlet,  Steven Mortillo,  Robert Jeyaseelan Sr,  Benjamin Henley,  Ravindra Tejwani,  Rajeev S Bhide,  George L Trainor,  Joseph Fargnoli,  Louis J Lombardo
Affiliations

Affiliation

  • 1 Bristol-Myers Squibb, Research and Development, Candiac, Que., Canada J5R 1J1. [email protected]
PMID: 18395443 DOI: 10.1016/j.bmcl.2008.03.057
Abstract

We report herein a series of substituted N-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amines as inhibitors of vascular endothelial growth factor receptor-2 tyrosine kinase. Through structure-activity relationship studies, biochemical potency, pharmacokinetics, and kinase selectivity were optimized to afford BMS-645737 (13), a compound with good preclinical in vivo activity against human tumor xenograft models.

Figures
Products